Results 11 to 20 of about 7,410 (157)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer

open access: yesFrontiers in Cell and Developmental Biology, 2021
Bruton’s tyrosine kinase (BTK) is a soluble tyrosine kinase with central roles in the development, maturation, and signaling of B cells. BTK has been found to regulate cell proliferation, survival, and migration in various B-cell malignancies.
Xianhui Wang   +3 more
doaj   +1 more source

Regulatory phosphorylation of Ikaros by Bruton's tyrosine kinase. [PDF]

open access: yesPLoS ONE, 2013
Diminished Ikaros function has been implicated in the pathogenesis of acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Therefore, a stringent regulation of Ikaros is of paramount importance for normal lymphocyte ontogeny ...
Hong Ma   +5 more
doaj   +1 more source

Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema [PDF]

open access: yesJAAD Case Reports
Shannon Meledathu, BS   +4 more
doaj   +2 more sources

Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA). [PDF]

open access: yes, 1994
The gene responsible for X-linked agammaglobulinemia (XLA) has been recently identified to code for a cytoplasmic tyrosine kinase (Bruton's agammaglobulinemia tyrosine kinase, BTK), required for normal B cell development. BTK, like many other cytoplasmic
Chen, SH   +11 more
core   +1 more source

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies

open access: yesFrontiers in Cell and Developmental Biology, 2021
Bruton’s tyrosine kinase (BTK) was discovered due to its importance in B cell development, and it has a critical role in signal transduction downstream of the B cell receptor (BCR).
Stefan F. H. Neys   +2 more
doaj   +1 more source

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

open access: yes, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani   +59 more
core   +1 more source

Disseminated fungal infection in a patient receiving zanubrutinib

open access: yesClinical Case Reports, 2023
Key Clinical Message We report a case of fatal disseminated aspergillosis in the setting of administration of zanubrutinib, a second‐generation Bruton's tyrosine kinase inhibitor thought to have a lower rate of immunosuppression‐related side effects.
Madalyn Walsh   +3 more
doaj   +1 more source

Immunomodulating effects of antitumor drugs Bruton tyrosine kinase inhibitors and the possibility of their use in allergic and infectious diseases

open access: yesМедицинская иммунология, 2023
Bruton's tyrosine kinase (BTK) inhibitors represent a class of drugs that have demonstrated their efficacy and safety in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphomas who were considered refractory to any previously used type of ...
Yu. S. Torshina   +4 more
doaj   +1 more source

Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals [PDF]

open access: yes, 2016
Chemo immunotherapies for chronic lymphocytic leukemia (CLL) showed a positive impact on clinical outcome, but many patients relapsed or become refractory to the available treatments.
Facco, Monica   +7 more
core   +1 more source

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.

open access: yesPLoS ONE, 2017
Activated B-cell-like diffuse large B-cell lymphoma relies on B-cell receptor signaling to drive proliferation and survival. Downstream of the B-cell receptor, the key signaling kinases Bruton's tyrosine kinase and phosphoinositide 3-kinase δ offer ...
Anella Yahiaoui   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy